Characterization of tumor suppressive function of P300/CBP-associated factor at frequently deleted region 3p24 in esophageal squamous cell carcinoma

Oncogene

Volumn 28, Issue 31, 2009, Pages 2821-2828

  Zhu, C ^a   Qin, Y R ^b   Xie, D ^c   Chua, D T T ^a   Fung, J M ^a   Chen, L ^a   Fu, L ^a   Hu, L ^a   Guan, X Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Esophageal squamous cell carcinoma; Loss of heterozygosity; Methylation; PCAF; Tumor suppressor gene

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AGAR; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HISTONE ACETYLTRANSFERASE PCAF; RETINOBLASTOMA PROTEIN; SMAD PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CARCINOGENICITY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHROMOSOME 3P; CHROMOSOME DELETION; COLONY FORMATION; CONTROLLED STUDY; DEMETHYLATION; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; METHYLATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 3; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASMS, EXPERIMENTAL; P300-CBP TRANSCRIPTION FACTORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HETEROLOGOUS;

MUS MUSCULUS;

EID: 68349125550     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.137     Document Type: Article

References (31)

1. Atadja P, Wong H, Veillete C, Riabowol K. (1995). Overexpression of cyclin Dl blocks proliferation of normal diploid fibroblasts. Exp Cell Res 217: 205-216.
2. Cao ZA, Daniel D, Hanahan D. (2002). Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer 2: 11.
3. Carnero A, Hannon GJ. (1998). The INK4 family of CDK inhibitors. Curr Top Microbiol Immunol 227: 43-55.
4. Chan HM, Krstic-Demonacos M, Smith L, Demonacos C, La Thangue NB. (2001). Acetylation control of the retinoblastoma tumour-suppressor protein. Nat Cell Biol 3: 667-674.
5. Chiao PJ, Hunt KK, Grau AM, Abramian A, Fleming J, Zhang W et al. (1999). Tumor suppressor gene Smad4/DPC4, its downstream target genes, and regulation of cell cycle. Ann N Y Acad Sci 880: 31-37.
6. de Jong JS, van Diest PJ, Michalides RJ, van der Valk P, Meijer CJ, Baak JP. (1998). Correlation of cyclin Dl and Rb gene expression with apoptosis in invasive breast cancer. Mol pathol 51: 30-34.
7. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A et al. (2006). Cosmic 2005. Br J Cancer 94: 318-322.
8. Fu L, Qin YR, Xie D, Hu L, Kwong DL, Srivastava G et al. (2007). Characterization of a novel tumor-suppressor gene PLC delta 1 at 3p22 in esophageal squamous cell carcinoma. Cancer Res 67: 10720-10726.
9. Guan XY, Sham JS, Tang TC, Fang Y, Huo KK, Yang JM. (2001). Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res 61: 3806-3809.
10. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. (1999). Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through Gl. Cell 98: 859-869.
11. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. (2005). Cancer statistics, 2005. CA Cancer J Clin 55: 10-30.
12. Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M et al. (2003). Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 63: 3724-3728.
13. Kwong D, Lam A, Guan X, Law S, Tai A, Wong J et al. (2004). Chromosomal aberrations in esophageal squamous cell carcinoma among Chinese: gain of 12p predicts poor prognosis after surgery. Hum Pathol 35: 309-316.
14. Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T. (2000). Regulation of E2F1 activity by acetylation. EMBO J 19: 662-671.
15. Offner FA. (2000). [Etiology, molecular biology and pathology of squamous cell carcinoma of the esophagus]. Pathologe 21: 349-357.
16. Ogasawara S, Maesawa C, Tamura G, Satodate R. (1995). Frequent microsatellite alterations on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 55: 891-894.
17. Ogryzko VV, Kotani T, Zhang X, Schiltz RL, Howard T, Yang XJ et al. (1998). Histone-like TAFs within the PCAF histone acetylase complex. Cell 94: 35-44.
18. Pack SD, Karkera JD, Zhuang Z, Pak ED, Balan KV, Hwu P et al. (1999). Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridization reveals a consistent pattern of chromosomal alterations. Genes Chromosomes Cancer 25: 160-168.
19. Qin YR, Fu L, Sham PC, Kwong DL, Zhu CL, Chu KK et al. (2008). Single-nucleotide polymorphism-mass array reveals commonly deleted regions at 3p22 and 3p14.2 associate with poor clinical outcome in esophageal squamous cell carcinoma. Int J Cancer 123: 826-830.
20. Schiltz RL, Nakatani Y. (2000). The PCAF acetylase complex as a potential tumor suppressor. Biochim Biophys Acta 1470: M37-M53.
21. Shimada Y, Imamura M, Wagata T, Yamaguchi N, Tobe T. (1992). Characterization of 21 newly established esophageal cancer cell lines. Cancer 69: 277-284.
22. Tanaka H, Shibagaki I, Shimada Y, Wagata T, Imamura M, Ishizaki K. (1996). Chracterization of p53 gene mutations in esophageal squamous cell carcinoma cell lines: increased frequency and different spectrum of mutations from primary tumors. Int J Cancer 65: 372-376.
23. Ullmannova V, Stockbauer P, Hradcova M, Soucek J, Haskovec C. (2003). Relationship between cyclin D1 and p21(Wafl/Cipl) during differentiation of human myeloid leukemia cell lines. Leuk Res 27: 1115-1123.
24. Vogelstein B, Lane D, Levine AJ. (2000). Surfing the p53 network. Nature 408: 307-310.
25. Wang X, Pan L, Feng Y, Wang Y, Han Q, Han L et al. (2008). P300 plays a role in p16(INK4a) expression and cell cycle arrest. Oncogene 27: 1894-1904.
26. Watts GS, Oshiro MM, Junk DJ, Wozniak RJ, Watterson S, Domann FE et al. (2004). The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells. Neoplasia 6: 187-194.
27. Xie D, Sham JS, Zeng WF, Lin HL, Che LH, Wu HX et al. (2003). Heterogeneous expression and association of beta-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer 107: 896-902.
28. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y. (1996). A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382: 319-324.
29. Yen CC, Chen YJ, Chen JT, Hsia JY, Chen PM, Liu JH et al. (2001). Comparative genomic hybridization of esophageal squamous cell carcinoma: correlations between chromosomal aberrations and disease progression/prognosis. Cancer 92: 2769-2777.
30. Zhang C, Li K, Wei L, Li Z, Yu P, Teng L et al. (2007). p300 expression repression by hypermethylation associated with tumour invasion and metastasis in oesophageal squamous cell carcinoma. J Clin Pathol 60: 1249-1253.
31. Zhao LY, Liu Y, Bertos NR, Yang XJ, Liao D. (2003). PCAF is a coactivator for p73-mediated transactivation. Oncogene 22: 8316-8329.